Xtant Medical (NYSEAMERICAN:XTNT) Share Price Crosses Above Two Hundred Day Moving Average – Should You Sell?

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) shares passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.68 and traded as high as $0.8099. Xtant Medical shares last traded at $0.7840, with a volume of 139,917 shares trading hands.

Analyst Ratings Changes

Separately, BTIG Research cut their target price on shares of Xtant Medical from $2.00 to $1.50 and set a “buy” rating for the company in a research note on Tuesday, November 11th. One investment analyst has rated the stock with a Buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $1.50.

Xtant Medical Price Performance

The business has a 50-day moving average price of $0.73 and a two-hundred day moving average price of $0.68. The company has a quick ratio of 1.06, a current ratio of 2.21 and a debt-to-equity ratio of 0.35. The company has a market capitalization of $109.76 million, a price-to-earnings ratio of 78.48 and a beta of -0.08.

Xtant Medical (NYSEAMERICAN:XTNT) last announced its quarterly earnings results on Monday, November 10th. The medical device company reported $0.01 EPS for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.02. Xtant Medical had a net margin of 1.32% and a return on equity of 3.77%. The business had revenue of $27.77 million during the quarter, compared to analyst estimates of $32.70 million.

Hedge Funds Weigh In On Xtant Medical

A number of hedge funds have recently added to or reduced their stakes in XTNT. Jane Street Group LLC purchased a new stake in shares of Xtant Medical in the second quarter worth approximately $26,000. Mink Brook Asset Management LLC grew its holdings in Xtant Medical by 125.8% during the second quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company’s stock worth $81,000 after buying an additional 60,997 shares in the last quarter. Crescent Grove Advisors LLC raised its position in Xtant Medical by 94.3% in the 2nd quarter. Crescent Grove Advisors LLC now owns 412,024 shares of the medical device company’s stock valued at $304,000 after buying an additional 200,000 shares during the last quarter. Vanguard Group Inc. lifted its stake in Xtant Medical by 4.6% during the 3rd quarter. Vanguard Group Inc. now owns 2,355,671 shares of the medical device company’s stock valued at $1,529,000 after acquiring an additional 104,159 shares in the last quarter. Finally, AWM Investment Company Inc. bought a new position in Xtant Medical during the 2nd quarter valued at $4,875,000. Institutional investors and hedge funds own 69.33% of the company’s stock.

Xtant Medical Company Profile

Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.